Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cometriq Thyroid Approval May Open Door For Use In Prostate Cancer

Executive Summary

As cabozantinib wins FDA approval for the rare medullary thyroid cancer, Exelixis stresses its broader development program in other tumor types, notably prostate cancer. The company is likely to submit prostate cancer data to compendia, which if successful could enable reimbursement for the off-label use.

You may also be interested in...



ASCO Round-Up: Array, Kite, Exelixis, Pfizer/Merck KGAA, Mylan, Novartis

The annual American Society of Clinical Oncology (ASCO) conference has been ongoing the last several days in Chicago, giving companies the chance to showcase their work in a range of cancers. Here's a look at some of the highlights.

Exelixis’ Cabozantinib Cleared For Kidney Cancer, With Competitive Labeling

Company plans to launch within two weeks, priced at a premium to competing drugs in kidney cancer.

Bristol, Exelixis Trials Preview Changes In Kidney Cancer Market

Commenting on pivotal trial success for Bristol’s checkpoint immunotherapy Opdivo and targeted Cometriq in renal cancer, Exelixis CEO Michael Morrissey says there’s room for two new different drugs for kidney cancer, and points out that an early stage study combining them is under way.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel